Jaypirca (pirtobrutinib) receives expanded indication from US FDA for 1L CLL/SLL patients October 6, 2026
FDA Approves Lyrfigtu (Lirafugratinib) for 2L Cholangiocarcinoma with FGFR2 Fusion or Other Rearrangement Treatment Option October 1, 2026
FDA approves BRAVNETSA™ (lutetium Lu 177 dotatate) for patients with SSR+ve GEP-NETs, including foregut, midgut, and hindgut NEC tumors October 1, 2026
FDA Approves WELIREG + LENVIMA for Certain Previously Treated Adult Patients With clear cell RCC October 1, 2026
FDA approves imlunestrant in combination with abemaciclib for ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer September 22, 2026
KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph) Approved in Japan for SubQ Administration for All KEYTRUDA Indications Approved in Japan September 22, 2026
FDA approves BEXLUTRY lutetium Lu 177 dotatate injection for adults with SSTR-positive GEP-NETs September 22, 2026
Etcamah + CDK4/6 inhibitor combo approved in the US for 1L advanced HR-positive breast cancer September 9, 2026
FDA Approves Ziihera® (zanidatamab-hrii) with and without Tislelizumab + Chemo in 1L HER2+ Advanced Gastroesophageal Adenocarcinoma September 2, 2026
European Commission approves TECVAYLI (teclistamab) plus daratumumab for relapsed/refractory multiple myeloma August 25, 2026
FDA Grants Accelerated Approval to ZENBEXUS in Combination with Daratumumab and Hyaluronidase-fihj and Dexamethasone (ZDd) for Patients with Multiple Myeloma August 20, 2026
NMPA approves felzartamab (Jingfei) + lenalidomide and dexamethasone for treating multiple myeloma patients who have received at least one prior line of therapy August 20, 2026
Ivonescimab + Chemo Approved in China by NMPA for 1L Treatment of Patients with Squamous NSCLC August 20, 2026
FDA grants Accelerated Approval to TUDRIQEV + Nivolumab combo for Unresectable Advanced Cutaneous Melanoma After Progression on an anti-PD-1 Based Regimen August 11, 2026
Datroway approved in the EU for 1L metastatic TNBC patients not candidates for immunotherapy August 5, 2026
Etcamah (camizestrant) in combination with a CDK4/6 inhibitor approved in the EU for 1L advanced ER-positive breast cancer July 28, 2026
FDA grants traditional approval to selpercatinib for locally advanced or metastatic RET fusion-positive solid tumors July 21, 2026
FDA approves SC Sarclisa (isatuximab-irfc) Escena + SOC for multiple myeloma patients across all existing indications of Sarclisa IV formulation July 15, 2026
FDA Approves REVTORPYK (gedatolisib) for the Treatment of HR+/HER2-, PIK3CA WT Locally Advanced or Metastatic Breast Cancer July 15, 2026
FDA Approves KEYTRUDA and KEYTRUDA QLEX, Each With Padcev, as Treatment Before and After Surgery for Adults With MIBC July 15, 2026
